Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
08/2011
08/04/2011US20110189271 Pharmaceutical formulations of acid-labile drugs
08/04/2011US20110189270 Differential Loading Of Drug-Eluting Medical Devices
08/04/2011US20110189269 Extended release composition containing tramadol
08/04/2011US20110189266 Corticosteroid microvesicles for treatment of cardiovascular diseases
08/04/2011US20110189264 Group of Nucleic Acid Fragments for Prevention of HIV Infection or AIDS and the Usage Thereof
08/04/2011US20110189262 Methods and Compositions for Reducing Systemic Toxicity of Vectors
08/04/2011US20110189261 Transdermally absorbable preparation
08/04/2011US20110189260 Use of zinc chelators to inhibit biofilm formation
08/04/2011US20110189259 Multidirectional mucosal delivery devices and methods of use
08/04/2011US20110189258 Method and compositions for inhibition of double stranded dna viruses
08/04/2011US20110189257 Nanoparticle based therapy for aggregating mucin
08/04/2011US20110189256 Reduction of infection associated with medical device
08/04/2011US20110189255 Drug-eluting stents for adenosine receptor modulation
08/04/2011US20110189252 Pharmaceutical compositions comprising lignans and their derivatives for treating hyperplastic diseases
08/04/2011US20110189243 Pharmaceutical formulation for lowering pulmonary blood pressure
08/04/2011US20110189241 Process For Controlling The Particle Size of A [3-(Trifluoromethyl)Phenyl]-1-Aminopropane Derivative
08/04/2011US20110189237 Therapeutic Agent for Malignant Mesothelioma and Immunostimulant
08/04/2011US20110189214 Cdca1 epitope peptides and vaccines containing the same
08/04/2011US20110189213 Mybl2 epitope peptides and vaccines containing the same
08/04/2011US20110189212 Oxidized lipids and uses thereof in the treatment of inflammatory diseases and disorders
08/04/2011US20110189210 Method of inhibiting remnant lipoprotein production
08/04/2011US20110189205 Methods of treating cancer using an agent that modulates activity of the calcitonin-gene related peptide ("cgrp") receptor
08/04/2011US20110189204 Treatment of Disease with Proteasone Inhibitors
08/04/2011US20110189202 Compositions comprising soluble cd84 or anti-cd84 antibodies and methods for diagnosing and treating b-cll
08/04/2011US20110189201 Modulation of bone development
08/04/2011US20110189199 Methods for p2ry5 mediated regulation of hair growth and mutants thereof
08/04/2011US20110189195 Method for controlling cancer metastasis or cancer cell migration by modulating the cellular level of lysyl trna synthetase
08/04/2011US20110189193 Cell lines and host nucleic acid sequences related to infectious disease
08/04/2011US20110189192 Novel compounds that are erk inhibitors
08/04/2011US20110189191 Methods and Compositions for Treating Conditions of the Eye
08/04/2011US20110189187 Novel immunogenic compositions for the prevention and treatment of meningococcal disease
08/04/2011US20110189184 Modulation of neural stem cells and neural progenitor cells
08/04/2011US20110189175 Chronic lymphocytic leukemia prognosis and treatment
08/04/2011US20110189174 Compositions and methods for treating, reducing, ameliorating, alleviating, or inhibiting progression of, pathogenic ocular neovascularization
08/04/2011US20110189173 PHOSPHORYLATED C-ErbB2 AS A SUPERIOR PREDICTIVE THERANOSTIC MARKER FOR THE DIAGNOSIS AND TREATMENT OF CANCER
08/04/2011US20110189167 Methods and Compositions for the Treatment of Myeloproliferative Diseases and other Proliferative Diseases
08/04/2011US20110189165 Method of identifying disease risk factors
08/04/2011US20110189160 Veterinary Topical Agent
08/04/2011US20110189155 Large Form Of Human 2',5'-Oligoadenylate Synthetase OAS3 for Preventing or Treating Infection With Positive-Sense Single-Stranded RNA Viruses
08/04/2011US20110189152 Combination composition, comprising as active ingredients L-carnitine or propionyl L-carnitine, for the prevention or treatment of chronic venous insufficiency
08/04/2011US20110189151 Compositions and methods for prolonging survival of platelets
08/04/2011US20110189148 Lactose compositions with decreased lactose content
08/04/2011US20110189141 Multiple target t cell receptor
08/04/2011US20110189131 Active variants of the il-18 binding protein and medical uses thereof
08/04/2011US20110189130 Dihydropyrazolopyrimidinone derivatives
08/04/2011US20110189129 Hepatitis c virus inhibitors
08/04/2011US20110189127 Tricyclic indole derivatives and methods of use thereof
08/04/2011US20110189125 Modulators of HSP70/DnaK Function and Methods of Use Thereof
08/04/2011US20110189121 Bitablets comprising compacted polyallylamine polymer and method for the production thereof
08/04/2011US20110189120 Aegyptin and uses thereof
08/04/2011US20110189114 minoxidil composition and non-aerosol, non-spray foam method of delivery therefor
08/04/2011US20110189110 Compositions and methods for the treatment of xerostomia
08/04/2011US20110189107 Alpha-amylase inhibitors: the montbretins and uses thereof
08/04/2011US20110189106 Intranasal compositions, dosage forms and methods of treatment
08/04/2011US20110189105 Griffithsin, glycosylation-resistant griffithsin, and related conjugates, compositions, nucleic acids, vectors, host cells, methods of production and methods of use
08/04/2011US20110189103 Aerosolized Fosfomycin/Aminoglycoside Combination for the Treatment of Bacterial Respiratory Infections
08/04/2011US20110189097 Use of WNT inhibitor to inhibit angiogenesis in the CNS
08/04/2011US20110189092 Polymer-agent conjugates, particles, compositions, and related methods of use
08/04/2011US20110189091 Colon lavage system
08/04/2011US20110186457 Novel single unit carbapenem aminoglycoside formulations
08/04/2011DE102010044870A1 Hemmung des Überlebens von Mundhöhlenkrebs durch Cyclohexenonverbindungen aus Antrodia camphorata Inhibition of survival of oral cancer by cyclohexenone from Antrodia camphorata
08/04/2011DE102009041241A1 New heteroaromatic compounds are hypoxia-inducible factor inhibitors useful to treat and/or prevent e.g. cancer or tumor diseases, heart attack, arrhythmia, stroke, psoriasis, diabetic retinopathy, rheumatoid arthritis and polycythemia
08/04/2011CA2851105A1 Polynucleotide encoding acyl-coa synthetase homolog and use thereof
08/04/2011CA2788425A1 Ph-responsive fluorescent false neurotransmitters and their use
08/04/2011CA2788417A1 Trypsin-like serine protease inhibitors, and their preparation and use
08/04/2011CA2788366A1 Compositions comprising sugar-cysteine products
08/04/2011CA2788364A1 7-azoniabicyclo [2.2.1] heptane derivatives, methods of production, and pharmaceutical uses thereof
08/04/2011CA2788348A1 Therapies for treating hepatitis c virus infection
08/04/2011CA2788334A1 Polymorphic forms of lubiprostone
08/04/2011CA2788326A1 Compounds for use in the treatment of diseases
08/04/2011CA2788317A1 Methods of preparing thiazolidines
08/04/2011CA2788224A1 Pyrazole compounds as crth2 antagonists
08/04/2011CA2788155A1 Polyheterocyclic compounds highly potent as hcv inhibitors
08/04/2011CA2788150A1 Compounds for suppressing a peripheral nerve disorder induced by an anti-cancer agent
08/04/2011CA2788146A1 Sorafenib dimethtyl sulphoxide solvate
08/04/2011CA2788078A1 Compositions and methods for prevention and treatment of pulmonary hypertension
08/04/2011CA2788073A1 Di-substituted pyridine derivatives as anticancers
08/04/2011CA2787946A1 Therapeutically active cyclopentanes
08/04/2011CA2787914A1 Therapeutic agents for treatment of ocular hypertension
08/04/2011CA2787785A1 Compositions and methods for enhancing proteasome activity
08/04/2011CA2787784A1 Small molecules for the modulation of mcl-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders
08/04/2011CA2787568A1 Formulations of bendamustine
08/04/2011CA2787407A1 5-alkynyl-pyrimidines
08/04/2011CA2787396A1 5-alkynyl pyrimidines and their use as kinase inhibitors
08/04/2011CA2787363A1 Pyrazolopyrimidine kinase inhibitors
08/04/2011CA2787323A1 Therapeutic or prophylactic agent for biliary tract diseases
08/04/2011CA2787321A1 Pyrazolopyridine kinase inhibitors
08/04/2011CA2787315A1 Pyrazolopyridine kinase inhibitors
08/04/2011CA2786994A1 Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
08/04/2011CA2786888A1 Pharmaceutical compositions for the treatment of pain and other indications
08/04/2011CA2786802A1 Composition for exterminating animal parasite comprising an aromatic carboxamide derivative and method thereof
08/04/2011CA2786509A1 Sulfonamido derivatives of 3,4-diarylpyrazoles as protein kinase inhibitors
08/04/2011CA2786245A1 Substituted naphthyridines and their use as syk kinase inhibitors
08/04/2011CA2785528A1 Nutritional emulsions comprising calcium hmb
08/04/2011CA2785524A1 Nutritional powders comprising spray dried hmb
08/04/2011CA2785522A1 Nutritional emulsions comprising calcium hmb and soluble protein
08/04/2011CA2784718A1 Topical antiparasitic formulations
08/04/2011CA2784571A1 Oxygen-substituted 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals
08/04/2011CA2784330A1 4'-azido-nucleosides as anti-hcv compunds
08/04/2011CA2783420A1 Prophylactic or therapeutic agent for crohn's disease comprising organic acid polymer as active ingredient